Citations

Showing 10 of 108094 citations.

Middle Fossa Approach for Resection of a Petrous Apex Cholesterol Granuloma: 2-Dimensional Operative Video
Weisskopf, Peter A., Turcotte, Evelyn L. , Rahme, Rudy J. , Bendok, Bernard R. , Bendok, Bernard R

Mayo Clinic

Operative Neurosurgery | September 14, 2022 | Volume: 23 | Issue: 5 | Pages: e322-e323

10.1227/ons.0000000000000374 | PMID 36103353 Get It

Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination
Caldera, Freddy , Necela, Brian M. , Cogen, Davitte , Saha, Sumona , Wald, Arnold , Daoud, Nader , Chun, Kelly , Grimes, Ian, Lutz, Megan , Helden, Sean R Van, Swift, Melanie D. , Virk, Abinash , Bharucha, Adil E. , Chumsri, Saranya , Knutson, Keith L. , Saha, Sumona , Swift, Melanie D , Caldera, Freddy , Farraye, Francis A. , Helden, Sean R. Van , Patel, Tushar , Gores, Gregory J. , Hayney, Mary S. , Knutson, Keith L.

Mayo Clinic

Inflammatory Bowel Diseases | September 14, 2022 | Volume: 29 | Issue: 8 | Pages: 1202-1209

10.1093/ibd/izac193 | PMID 36103273 Get It

Abstract Background Some patients with inflammatory bowel disease (IBD) on immunosuppressive therapies may have a blunted response to certain vaccines, including the messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines. However, few studies have evaluated the cell-mediated immune response (CMIR), which is critical to host defense after COVID-19 infection. The aim of this study was to evaluate the humoral immune response and CMIR after mRNA COVID-19 vaccination in patients with IBD. Methods This prospective study (HERCULES [HumoRal and CellULar initial and Sustained immunogenicity in patients with IBD] study) evaluated humoral immune response and CMIR after completion of 2 doses of mRNA COVID-19 vaccines in 158 IBD patients and 20 healthy control (HC) subjects. The primary outcome was the CMIR to mRNA COVID-19 vaccines in patients with IBD. The secondary outcomes were a comparison of (1) the CMIR in patients with IBD and HC subjects, (2) CMIR and humoral immune response in all participants, and (3) correlation between CMIR and humoral immune response. Results The majority (89%) of patients with IBD developed a CMIR, which was not different vs HC subjects (94%) (P = .6667). There was no significant difference (P = .5488) in CMIR between immunocompetent (median 255 [interquartile range, 146-958] spike T cells per million peripheral blood mononuclear cells) and immunosuppressed patients (median 377 [interquartile range, 123-1440]). There was no correlation between humoral and cell-mediated immunity after vaccination (P = .5215). In univariable analysis, anti-tumor necrosis factor therapy was associated with a higher CMIRs (P = .02) and confirmed in a multivariable model (P = .02). No other variables were associated with CMIR. Conclusions Most patients with IBD achieved CMIR to a COVID-19 vaccine. Future studies are needed evaluating sustained CMIR and clinical outcomes.
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
Evaluation of evidence supporting NICE recommendations to change people's lifestyle in clinical practice: cross sectional survey
Albarqouni, Loai , Ringsten, Martin , Montori, Víctor M. , Jørgensen, Karsten Juhl , Johansson, Minna , Montori, Victor M , Johansson, Minna , Bulbeck, Helen

Mayo Clinic

BMJ Medicine | September 14, 2022 | Volume: 1 | Issue: 1 | Pages: e000130

10.1136/bmjmed-2022-000130 | PMID 36936567 Get It

Objectives To assess whether recommendations of individually oriented lifestyle interventions (IOLIs) in guidelines from the National Institute for Health and Care Excellence (NICE) were underpinned by evidence of benefit, and whether harms and opportunity costs were considered. Design Cross sectional survey. Setting UK. Data sources NICE guidelines and supporting evidence. Eligibility criteria All NICE pathways for IOLI recommendations (ie, non-drug interventions that healthcare professionals administer to adults to achieve a healthier lifestyle and improve health) were searched systematically on 26 August 2020. One author screened all retrieved pathways for candidate guidelines, while a second author verified these judgments. Two authors independently and in duplicate screened all retrieved guidelines and recommendations for eligibility, extracted data, and evaluated the evidence cited and the outcomes considered. Disagreements were noted and resolved by consensus. Results Within 57 guidelines, 379 NICE recommendations were found for IOLIs; almost all (n=374; 99%) recommended the lifestyle intervention and five (1%) recommended against the intervention. Of the 379 recommendations, 13 (3%) were supported by moderate or high certainty evidence of a beneficial effect on patient relevant outcomes (n=7; 2%) or surrogate outcomes (n=13; 3%). 19 (5%) interventions considered psychosocial harms, 32 (8%) considered physical harms, and one (<1%) considered the opportunity costs of implementation. No intervention considered the burden placed on individuals by these recommendations. Conclusion Few NICE recommendations of lifestyle interventions are supported by reliable evidence. While this finding does not contest the beneficial effects of healthy habits, guidelines recommending clinicians to try to change people’s lifestyle need to be reconsidered given the substantial uncertainty about the effectiveness, harms, and opportunity costs of such interventions.
Cricopharyngeus Muscle Dysfunction and Hypopharyngeal Diverticula (e.g., Zenker): A Multicenter Study
Howell, Rebecca J. , Ekbom, Dale C. , Kasperbauer, Jan L. , Tabangin, Meredith E. , Altaye, Mekibib , Wahab, Shaun A. , Belafsky, Peter C. , Allen, Jacqui , Bayan, Semirra L. , Cervenka, Brian , deSilva, Brad W. , Friedman, Aaron D. , Fritz, Mark A. , Giliberto, John Paul , Harmon, Jeffrey , Khosla, Sid , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Piraka, Cyrus , Rosen, Clark A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Yuen, Sonia , Postma, Greg, Ekbom, Dale , Kasperbauer, Jan , Tabangin, Meredith , Belafsky, Peter , Bayan, Semirra, Giliberto, John Paul , Bayan, Semirra , Dion, Gregory R. , Guardiani, Elizabeth , Kwak, Paul E. , Ma, Yue , Mayerhoff, Ross , Wilson, Keith, Wright, Carter

Mayo Clinic

The Laryngoscope | September 14, 2022 | Volume: 133 | Issue: 6 | Pages: 1349-1355

10.1002/lary.30387 | PMID 36102298 Get It

ObjectiveTo describe demographics and imaging and compare findings and symptoms at presentation in a large cohort of persons with cricopharyngeus muscle dysfunction (CPMD) with and without hypopharyngeal diverticula.MethodologyProspective, multicenter cohort study of all individuals enrolled in the Prospective OUtcomes of Cricopharyngeal Hypertonicity (POUCH) Collaborative. Patient survey, comorbidities, radiography, laryngoscopy findings, and patient‐reported outcome measures (e.g., Eating Assessment Tool [EAT‐10]) data were abstracted from a REDCap database and summarized using means, medians, percentages, and frequencies. Diagnostic categories were compared using analysis of variance.ResultsA total of 250 persons were included. The mean age (standard deviation [SD]) of the cohort was 69.0 (11.2). Forty‐two percent identified as female. Zenker diverticula (ZD) was diagnosed in 85.2%, 9.2% with CPMD without diverticula, 4.4% with a Killian Jamieson diverticula (KJD), and 1.2% traction‐type diverticula. There were no differences between diagnostic categories in regard to age, gender, and duration of symptoms (p = 0.25, 0.19, 0.45). The mean (SD) EAT‐10 score for each group was 17.1 (10.1) for ZD, 20.2 (9.3) for CPMD, and 10.3 (9.4) for KJD. Patients with isolated CPMD had significantly greater EAT‐10 scores compared to the other diagnostic groups (p = 0.03).ConclusionZD is the most common, followed by CPMD without diverticula, KJD, and traction‐type. Patients with isolated obstructing CPMD may be more symptomatic than persons with ZD or KJD.Level of Evidence4 Laryngoscope, 133:1349–1355, 2023
The Amino Acid Homoarginine Inhibits Atherogenesis by Modulating T-Cell Function
Nitz, Katrin , Bianchini, Mariaelvy , Wichapong, Kanin , Avcilar-Kücükgöze, Irem , Bonfiglio, Cecilia Assunta , Migheli, Roberta , Wu, Yuting , Bürger, C., Li, Yuanfang , Forné, Ignasi , Mohanta, Sarajo K. , Duchêne, Johan , Heemskerk, Johan W. M. , Huveneers, Stephan , Lygate, Craig A. , Santovito, Donato , Zimmer, Ralf , Weber, Christian , Atzler, Dorothee , Nitz, Katrin , Wichapong, Kanin , Bonfiglio, Cecilia A , Migheli, Roberta , Li, Yuanfang , Forné, Ignasi , Ammar, Constantin , Janjic, Aleksandar , Heemskerk, Johan W M , Schwedhelm, Edzard , Huveneers, Stephan , Lygate, Craig A , Santovito, Donato , Zimmer, Ralf , Weber, Christian , Atzler, Dorothee , Nitz, Katrin , Nitz, Katrin , Lacy, Michael , Janjic, Aleksandar , Megens, Remco T. A. , Imhof, Axel , Lutgens, Esther

Mayo Clinic

Circulation Research | September 14, 2022 | Volume: 131 | Issue: 8 | Pages: 701-712

10.1161/circresaha.122.321094 | PMID 36102188 Get It

Background: Amino acid metabolism is crucial for inflammatory processes during atherogenesis. The endogenous amino acid homoarginine is a robust biomarker for cardiovascular outcome and mortality with high levels being protective. However, the underlying mechanisms remain elusive. We investigated the effect of homoarginine supplementation on atherosclerotic plaque development with a particular focus on inflammation. Methods: Female ApoE-deficient mice were supplemented with homoarginine (14 mg/L) in drinking water starting 2 weeks before and continuing throughout a 6-week period of Western-type diet feeding. Control mice received normal drinking water. Immunohistochemistry and flow cytometry were used for plaque- and immunological phenotyping. T cells were characterized using mass spectrometry–based proteomics, by functional in vitro approaches, for example, proliferation and migration/chemotaxis assays as well as by super-resolution microscopy. Results: Homoarginine supplementation led to a 2-fold increase in circulating homoarginine concentrations. Homoarginine-treated mice exhibited reduced atherosclerosis in the aortic root and brachiocephalic trunk. A substantial decrease in CD3 + T cells in the atherosclerotic lesions suggested a T-cell–related effect of homoarginine supplementation, which was mainly attributed to CD4 + T cells. Macrophages, dendritic cells, and B cells were not affected. CD4 + T-cell proteomics and subsequent pathway analysis together with in vitro studies demonstrated that homoarginine profoundly modulated the spatial organization of the T-cell actin cytoskeleton and increased filopodia formation via inhibition of Myh9 (myosin heavy chain 9). Further mechanistic studies revealed an inhibition of T-cell proliferation as well as a striking impairment of the migratory capacities of T cells in response to relevant chemokines by homoarginine, all of which likely contribute to its atheroprotective effects. Conclusions: Our study unravels a novel mechanism by which the amino acid homoarginine reduces atherosclerosis, establishing that homoarginine modulates the T-cell cytoskeleton and thereby mitigates T-cell functions important during atherogenesis. These findings provide a molecular explanation for the beneficial effects of homoarginine in atherosclerotic cardiovascular disease.
Safety and Efficacy of Revisional Surgery as a Treatment for Malnutrition after Bariatric Surgery
Vahibe, Ahmet , Aizpuru, Matthew J, Sarr, Michael G. , McKenzie, Travis J. , Ghanem, Omar M. , Mundi, Manpreet S. , Vierkant, Robert A. , Dayyeh, Barham K. Abu

Mayo Clinic

Journal of the American College of Surgeons | September 14, 2022 | Volume: 236 | Issue: 1 | Pages: 156-166

10.1097/xcs.0000000000000397 | PMID 36102543 Get It

BACKGROUND: Malnutrition after bariatric operation is a rare but potentially life-threatening complication. The safety and efficacy of revisional bariatric operation in malnourished patients are not well elucidated. STUDY DESIGN: We performed a retrospective chart review of patients who underwent revisional bariatric operation for severe malnutrition at our institution between 2008 and 2020. Associations of demographic and clinical characteristics with dichotomous outcomes of interest were examined using Fisher’s exact tests, Cochran-Armitage tests for trend, and two-sample t-tests when appropriate. RESULTS: Fifty-three patients underwent revisional bariatric operation for malnutrition from 2008 and 2020. The median follow-up was 24 months. The anatomy before revision was Roux-en-Y gastric bypass (n = 40, 75%), biliopancreatic diversion with duodenal switch (n = 6, 11%), sleeve gastrectomy (n = 4, 8%), and mini gastric bypass (n = 3, 6%). The percentage of patients requiring supplemental or total nutritional support decreased from 89% preoperatively (47% on enteral feedings and 42% on total parenteral nutrition (TPN) with or without tube feeding) to 13.2% at the last encounter after revision (7.5% still requiring enteral feedings and 5.7% on TPN). There was an association between the number of prior abdominal operations and postoperative pneumonia (p 0.03) and need for blood transfusion (p 0.01). There were no associations between major complications or last encounter nutrition and any preoperative variables other than age at the time of operation. There were 2 mortalities during a median follow-up of 24 months, and both occurred more than 1 year postoperatively. CONCLUSION: Revisional operation for severely malnourished bariatric operation patients is effective in the discontinuation of supportive nutrition. Postoperative complications are increased but not prohibitive.
Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer
Norain, Abdullah , Stucky, Chee‐Chee , Wasif, Nabil , Kalagara, Roshini, Kalagara, Roshini , Chang, Yu‐Hui

Mayo Clinic

Journal of the American College of Surgeons | September 14, 2022 | Volume: 235 | Issue: 6 | Pages: 829-837

10.1097/xcs.0000000000000407 | PMID 36102533 Get It

BACKGROUND: Current literature has identified textbook outcome (TO) as a quality metric after cancer surgery. We studied whether TO after pancreatic resection has a stronger association with long-term survival than individual hospital case volume. STUDY DESIGN: Patients undergoing surgery for pancreatic adenocarcinoma from 2010 to 2015 were identified from the National Cancer Database. Hospitals were stratified by volume (low less than 6, medium 6 to 19, and high 20 cases or more per year), and overall survival data were abstracted. We defined TO as adequate lymph node count, negative margins, length of stay less than the 75th percentile, appropriate systemic therapy, timely systemic therapy, and without a mortality event or readmission within 30 days. The association of TO and case volume was assessed using a multivariable Cox regression model for survival. RESULTS: Overall, 7270 patients underwent surgery, with 30.7%, 48.7%, and 20.6% performed at low-, medium-, and high-volume hospitals, respectively. Patients treated at low-volume hospitals were more likely to be Black, be uninsured or on Medicaid, have higher Charlson comorbidity scores, and be less likely to achieve TO (23.4% TO achievement vs 37.5% achievement at high-volume hospitals). However, high hospital volume was no longer associated with overall survival once TO was added to the multivariable model stratified by volume status. Achievement of TO corresponded to a 31% decrease in mortality (hazard ratio 0.69; p < 0.001), independent of hospital volume. CONCLUSIONS: Improved long-term survival after pancreatic resection was associated with TO rather than high hospital volume. Quality improvement efforts focused on TO criteria have the potential to improve outcomes irrespective of case volume.
N‐glycoproteomics reveals distinct glycosylation alterations in NGLY1‐deficient patient‐derived dermal fibroblasts
Budhraja, Rohit , Saraswat, Mayank , Graef, Diederik De , Ranatunga, Wasantha , Ramarajan, Madan Gopal , Mousa, Jehan , Pandey, Akhilesh , Morava, Éva , Budhraja, Rohit , De Graef, Diederik , Morava, Eva , Pandey, Akhilesh , Ramarajan, Madan G , Kozicz, Tamás

Mayo Clinic

Journal of Inherited Metabolic Disease | September 14, 2022 | Volume: 46 | Issue: 1 | Pages: 76-91

10.1002/jimd.12557 | PMID 36102038 Get It

AbstractCongenital disorders of glycosylation are genetic disorders that occur due to defects in protein and lipid glycosylation pathways. A deficiency of N‐glycanase 1, encoded by the NGLY1 gene, results in a congenital disorder of deglycosylation. The NGLY1 enzyme is mainly involved in cleaving N‐glycans from misfolded, retro‐translocated glycoproteins in the cytosol from the endoplasmic reticulum before their proteasomal degradation or activation. Despite the essential role of NGLY1 in deglycosylation pathways, the exact consequences of NGLY1 deficiency on global cellular protein glycosylation have not yet been investigated. We undertook a multiplexed tandem mass tags‐labeling‐based quantitative glycoproteomics and proteomics analysis of fibroblasts from NGLY1‐deficient individuals carrying different biallelic pathogenic variants in NGLY1. This quantitative mass spectrometric analysis detected 8041 proteins and defined a proteomic signature of differential expression across affected individuals and controls. Proteins that showed significant differential expression included phospholipid phosphatase 3, stromal cell‐derived factor 1, collagen alpha‐1 (IV) chain, hyaluronan and proteoglycan link protein 1, and thrombospondin‐1. We further detected a total of 3255 N‐glycopeptides derived from 550 glycosylation sites of 407 glycoproteins by multiplexed N‐glycoproteomics. Several extracellular matrix glycoproteins and adhesion molecules showed altered abundance of N‐glycopeptides. Overall, we observed distinct alterations in specific glycoproteins, but our data revealed no global accumulation of glycopeptides in the patient‐derived fibroblasts, despite the genetic defect in NGLY1. Our findings highlight new molecular and system‐level insights for understanding NGLY1‐CDDG.
My Virtual Cancer
Asadpoure, Alireza , chang, ying xian , Lee, A., Shahriyari, Leili , Abdel‐Rahman, Mohamed H. , Cebulla, Colleen M. , Hao, Wenrui , Jackson, Pamela , Mirzaei, Navid Mohammad , Stover, Daniel G. , Zervantonakis, Ioannis K.

Mayo Clinic

No container title available | September 14, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2172/1881930 Get It